Aduro BioTech, Inc. has three interconnected and complementary vaccine platforms that provide breadth and depth in developing vaccines for cancer, infectious diseases and biodefense: (a) live, attenuated Listeria monocytogenes, (b) GVAX and (c) cyclic dinucleotides (CDNs). The company's lead program is a randomized, controlled Phase 2 clinical trial of the sequential administration of Listeria-based CRS-207 and GVAX Pancreas in patients with metastatic pancreatic cancer. In addition, the company is conducting a Phase 1B trial with CRS-207 in patients with malignant pleural mesothelioma. The company is also evaluating the synergistic combination of CDNs and GVAX in preclinical tumor models. Moreover, the company's pipeline also includes preclinical programs in glioblastoma, prostate cancer, malaria, HBV and tularemia.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/31/13 | $6,500,000 | |||
| 01/09/15 | $51,400,000 | Series D |
Clough Capital Partners Foresite Capital Janus Capital Jennison Associates Morningside Group OrbiMed Advisors | undisclosed |
